Trial Profile
Retrospective, post-marketing safety surveillance study of Xarelto in patients with venous thromboembolisms
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 13 Dec 2016 New trial record
- 06 Dec 2016 Results (n=9638) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Results published in a Janssen Pharmaceuticals media release.